Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurocognitive comparison of first-line antiretroviral regimens in treatment-naive HIV-1 infection
2011-002656-14Phase 4Completed
- Sponsor
- Imperial College London
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atazanavir, darunavir, maraviroc, ritonavir, emtricitabine + tenofovir disoproxil and 1 more in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Imperial College London. Primary endpoint: Change in neurocognitive function at week 48. Started May 2012; status: completed.
02
Drugs
atazanavirdarunavirmaravirocritonaviremtricitabine + tenofovir disoproxil
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-002656-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002656-14.